Martinez H, Santos M, Pedraza L, Testera A
Mar Drugs. 2025; 23(2).
PMID: 39997193
PMC: 11857447.
DOI: 10.3390/md23020069.
Haque N, Parveen S, Tang T, Wei J, Huang Z
Mar Drugs. 2022; 20(8).
PMID: 36005531
PMC: 9410185.
DOI: 10.3390/md20080528.
Gao C, Wen C, Li Z, Lin S, Gao S, Ding H
Viruses. 2021; 13(5).
PMID: 33925713
PMC: 8144994.
DOI: 10.3390/v13050774.
Holzer S, Rzechorzek N, Short I, Jenkyn-Bedford M, Pellegrini L, Kilkenny M
ACS Chem Biol. 2019; 14(9):1904-1912.
PMID: 31479243
PMC: 6757278.
DOI: 10.1021/acschembio.9b00367.
Nitsche M, Christiansen H, Lederer K, Griesinger F, Schmidberger H, Pradier O
J Cancer Res Clin Oncol. 2012; 138(7):1113-20.
PMID: 22402597
PMC: 3605492.
DOI: 10.1007/s00432-012-1185-3.
Dynamic metabolic labeling of DNA in vivo with arabinosyl nucleosides.
Neef A, Luedtke N
Proc Natl Acad Sci U S A. 2011; 108(51):20404-9.
PMID: 22143759
PMC: 3251089.
DOI: 10.1073/pnas.1101126108.
Unrepairable DNA double-strand breaks initiate cytotoxicity with HSV-TK/ganciclovir.
Ladd B, OKonek J, Ostruszka L, Shewach D
Cancer Gene Ther. 2011; 18(10):751-9.
PMID: 21869826
PMC: 3176965.
DOI: 10.1038/cgt.2011.51.
Fludarabine in the treatment of chronic lymphocytic leukemia: a review.
Ricci F, Tedeschi A, Morra E, Montillo M
Ther Clin Risk Manag. 2009; 5(1):187-207.
PMID: 19436622
PMC: 2697528.
DOI: 10.2147/tcrm.s3688.
Cellular and biochemical mechanisms of the resistance of human cancer cells to a new anticancer ribo-nucleoside, TAS-106.
Shimamoto Y, Kazuno H, Murakami Y, Azuma A, Koizumi K, Matsuda A
Jpn J Cancer Res. 2002; 93(4):445-52.
PMID: 11985795
PMC: 5927010.
DOI: 10.1111/j.1349-7006.2002.tb01276.x.
Cellular and clinical pharmacology of fludarabine.
Gandhi V, Plunkett W
Clin Pharmacokinet. 2002; 41(2):93-103.
PMID: 11888330
DOI: 10.2165/00003088-200241020-00002.
Characterization of the deoxycytidine kinase promoter in human lymphoblast cell lines.
Chen E, Johnson 2nd E, Vetter S, Mitchell B
J Clin Invest. 1995; 95(4):1660-8.
PMID: 7706474
PMC: 295671.
DOI: 10.1172/JCI117841.
Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma.
Rodriguez G
Invest New Drugs. 1994; 12(2):75-92.
PMID: 7532163
DOI: 10.1007/BF00874436.
Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine.
Carson D, Wasson D, Beutler E
Proc Natl Acad Sci U S A. 1984; 81(7):2232-6.
PMID: 6585795
PMC: 345472.
DOI: 10.1073/pnas.81.7.2232.
Responses of human bone marrow progenitor cells to fluoro-ara-AMP, homoharringtonine, and elliptinium.
Umbach G, Hug V, Spitzer G, Thames H, Drewinko B
Invest New Drugs. 1984; 2(3):263-5.
PMID: 6210262
DOI: 10.1007/BF00175374.
Membrane transport and the antineoplastic action of nucleoside analogues.
Sirotnak F, Barrueco J
Cancer Metastasis Rev. 1987; 6(4):459-80.
PMID: 3327628
DOI: 10.1007/BF00047462.
Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: an Illinois Cancer Council Study.
Shevrin D, Lad T, Kilton L, Cobleigh M, BLOUGH R, Weidner L
Invest New Drugs. 1989; 7(2-3):251-3.
PMID: 2477345
DOI: 10.1007/BF00170869.
9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma.
Danhauser L, Plunkett W, Keating M, Cabanillas F
Cancer Chemother Pharmacol. 1986; 18(2):145-52.
PMID: 2431803
DOI: 10.1007/BF00262285.
Pharmacokinetic study of fludarabine phosphate (NSC 312887).
Hersh M, Kuhn J, Phillips J, Clark G, Ludden T, Von Hoff D
Cancer Chemother Pharmacol. 1986; 17(3):277-80.
PMID: 2427240
DOI: 10.1007/BF00256699.
Disposition and metabolism in mice of the potential antitumor and anti-human immunodeficiency virus-1 agent, 2-chloro-2',3'-dideoxyadenosine.
Chapman D, Powis G
Cancer Chemother Pharmacol. 1991; 27(4):285-9.
PMID: 1998984
DOI: 10.1007/BF00685113.
Fludarabine phosphate for the treatment of low grade lymphoid malignancy.
Whelan J, Davis C, Rule S, Ranson M, Smith O, Mehta A
Br J Cancer. 1991; 64(1):120-3.
PMID: 1713049
PMC: 1977289.
DOI: 10.1038/bjc.1991.253.
